Teriparatide

Description

Teriparatide

Also known as: Forteo, PTH 1-34

Teriparatide consists of the first 34 amino acids of parathyroid hormone (PTH). When administered intermittently, it promotes greater activation of osteoblasts compared to osteoclasts, leading to an overall increase in bone formation. This bone-building effect sets it apart from antiresorptive medications used for osteoporosis.
Approved by the FDA for the treatment of osteoporosis.

• A synthetic fragment of parathyroid hormone that promotes bone growth. Approved by the FDA for treating osteoporosis in individuals at high risk of fractures.
• Status: Approved by the FDA. Evidence level: Confirmed through FDA approval.
• Standard dosage: 20 mcg administered once daily via subcutaneous injection.
• Investigated uses: Management of osteoporosis, enhancement of bone formation, and reduction of fracture risk.